- Home
- LTC vs ORKA Comparison
LTC vs ORKA Comparison
Compare LTC & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LTC | ORKA |
|---|---|---|
| Founded | 1992 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | 1992 | N/A |
Fundamental Metrics
Financial Performance| Metric | LTC | ORKA |
|---|---|---|
| Price | $35.64 | $26.66 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | $39.00 | ★ $48.36 |
| AVG Volume (30 Days) | 405.5K | ★ 722.1K |
| Earning Date | 02-23-2026 | 11-12-2025 |
| Dividend Yield | ★ 6.39% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.72 | N/A |
| Revenue | ★ $226,987,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $22.49 | N/A |
| P/E Ratio | $49.50 | ★ N/A |
| Revenue Growth | ★ 14.23 | N/A |
| 52 Week Low | $31.70 | $5.49 |
| 52 Week High | $37.25 | $32.64 |
Technical Indicators
Market Signals| Indicator | LTC | ORKA |
|---|---|---|
| Relative Strength Index (RSI) | 60.05 | 40.41 |
| Support Level | $33.86 | $25.23 |
| Resistance Level | $34.70 | $28.51 |
| Average True Range (ATR) | 0.50 | 2.15 |
| MACD | 0.19 | -0.57 |
| Stochastic Oscillator | 84.79 | 19.03 |
Price Performance
Historical ComparisonAbout LTC LTC Properties Inc.
LTC Properties Inc is a healthcare facility real estate investment trust. The company operates one segment that works to invest in seniors housing and healthcare facilities through mortgage loans, property lease transactions, and other investments. Its real estate investments includes different types of properties such as Independent living communities, Assisted living communities, Memory care communities, Skilled nursing centers and other types of properties.
About ORKA Oruka Therapeutics Inc.
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.